Trastuzumab, a humanized monoclonal antibody that can be used against the extracellular domain of human epidermal growth factor receptor 2 (HER2), is an important component of the adjuvant therapy and metastasis therapy for HER2-positive breast cancers. Here, ERBB2 is linked to breast cancer.